Technical Analysis for CDAK - Codiak BioSciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| Historical CDAK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | -6.13% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.13% | |
| Wide Bands | Range Expansion | -6.13% | |
| Up 3 Days in a Row | Strength | -6.13% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.07% | |
| MACD Bullish Signal Line Cross | Bullish | 0.07% | |
| Narrow Range Bar | Range Contraction | 0.07% | |
| Wide Bands | Range Expansion | 0.07% | |
| Oversold Stochastic | Weakness | 0.07% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 4 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
| Fell Below 10 DMA | about 5 hours ago |
| Down 10% | about 5 hours ago |
| 60 Minute Opening Range Breakdown | about 6 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/12/2021
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Diseases Disease Urology Neurology Infectious Disease Exosome Neuromuscular Disease Vesicles
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Diseases Disease Urology Neurology Infectious Disease Exosome Neuromuscular Disease Vesicles
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.85 |
| 52 Week Low | 7.9 |
| Average Volume | 144,630 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 18.35 |
| 20-Day Moving Average | 15.45 |
| 10-Day Moving Average | 14.26 |
| Average True Range | 1.66 |
| ADX | 17.52 |
| +DI | 19.25 |
| -DI | 20.30 |
| Chandelier Exit (Long, 3 ATRs ) | 13.85 |
| Chandelier Exit (Short, 3 ATRs ) | 17.69 |
| Upper Bollinger Band | 18.47 |
| Lower Bollinger Band | 12.43 |
| Percent B (%b) | 0.35 |
| BandWidth | 39.12 |
| MACD Line | -1.08 |
| MACD Signal Line | -1.28 |
| MACD Histogram | 0.199 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.72 | ||||
| Resistance 3 (R3) | 16.75 | 16.05 | 16.35 | ||
| Resistance 2 (R2) | 16.05 | 15.50 | 16.04 | 16.23 | |
| Resistance 1 (R1) | 15.30 | 15.16 | 14.95 | 15.27 | 16.11 |
| Pivot Point | 14.60 | 14.60 | 14.43 | 14.59 | 14.60 |
| Support 1 (S1) | 13.85 | 14.05 | 13.50 | 13.82 | 12.97 |
| Support 2 (S2) | 13.15 | 13.71 | 13.14 | 12.85 | |
| Support 3 (S3) | 12.40 | 13.15 | 12.73 | ||
| Support 4 (S4) | 12.37 |
